Bipolar Disorder, Manic Clinical Trial
Official title:
Research on Optimization Program of Magnetic Seizure Therapy for Bipolar Mania Patients
This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety for bipolar mania. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).
Magnetic seizure therapy (MST) is likely to be an alternative options to electroconvulsive therapy (ECT). Widespread stimulation of cortical and subcortical regions is inevitable for ECT since the substantial impedance of the scalp and skull shuts most of the electrical stimulus away from the brain. Nevertheless, magnetic pulses are capable to focus the stimulus to a specific area of the brain because they can pass the scalp and skull without resistance. In Addition, electric current will penetrate into deeper structures, while magnetic stimulus are only capable to reach a depth of a few centimeters. As a consequence, MST are able to generate focus stimuli on superficial regions of the cortex while ECT can't, which may give MST the capability to produce comparable therapeutic benefits with the absence of apparent cognitive side effects. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03857438 -
Correlation of Audiovisual Features With Clinical Variables and Neurocognitive Functions in Bipolar Disorder, Mania
|
||
Completed |
NCT03013400 -
Ebselen as an add-on Treatment in Hypo/Mania
|
Phase 2 | |
Completed |
NCT04420793 -
Voice Changes During ECT
|
||
Withdrawn |
NCT03016104 -
Magnetic Seizure Therapy vs. Electroconvulsive Therapy for Bipolar Mania
|
N/A | |
Terminated |
NCT00329108 -
Ziprasidone And Olanzapine's Outcomes In Mania
|
Phase 4 | |
Terminated |
NCT04058249 -
Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder
|
N/A | |
Recruiting |
NCT06462586 -
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
|
Phase 3 | |
Not yet recruiting |
NCT06462612 -
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
|
Phase 3 |